OrbiMed Advisors
http://www.orbimed.com/OrbiMed is the world's largest healthcare-dedicated investment firm, with approximately $5 billion in assets under management. The firm was stated in 1989 with a vision to invest across the spectrum of healthcare companies: from private start-ups to large multinational companies.
View Older Stories View More Recent Stories
-
Form SC 13G Theravance Biopharma, Filed by: ORBIMED ADVISORS LLC
-
Form SC 13G Strongbridge Biopharma Filed by: ORBIMED ADVISORS LLC
-
Form SC 13G/A PROTHENA CORP PUBLIC Filed by: ORBIMED ADVISORS LLC
-
Form SC 13G OTONOMY, INC. Filed by: ORBIMED ADVISORS LLC
-
Form SC 13G/A ObsEva SA Filed by: ORBIMED ADVISORS LLC
-
Form SC 13G Mereo Biopharma Group Filed by: ORBIMED ADVISORS LLC
-
Form SC 13G/A MeiraGTx Holdings plc Filed by: ORBIMED ADVISORS LLC
-
Form SC 13G Larimar Therapeutics, Filed by: ORBIMED ADVISORS LLC
-
Form SC 13G/A Krystal Biotech, Inc. Filed by: ORBIMED ADVISORS LLC
-
Form SC 13G/A Kala Pharmaceuticals, Filed by: ORBIMED ADVISORS LLC
-
Form SC 13G/A Inspire Medical Systems, Filed by: ORBIMED ADVISORS LLC
-
Form SC 13G/A Harpoon Therapeutics, Filed by: ORBIMED ADVISORS LLC
-
Form SC 13G Forte Biosciences, Inc. Filed by: ORBIMED ADVISORS LLC
-
Form SC 13G/A FLUIDIGM CORP Filed by: ORBIMED ADVISORS LLC
-
Form SC 13G/A Crinetics Pharmaceutical Filed by: ORBIMED ADVISORS LLC
-
Form SC 13G/A Applied Therapeutics Filed by: ORBIMED ADVISORS LLC
-
Form SC 13G/A Aeglea BioTherapeutics, Filed by: ORBIMED ADVISORS LLC
-
Form SC 13G/A Adverum Biotechnologies, Filed by: ORBIMED ADVISORS LLC
-
Form 3 Decibel Therapeutics, For: Feb 11 Filed by: ORBIMED ADVISORS LLC
-
Form 3 Gemini Therapeutics, For: Feb 05 Filed by: ORBIMED ADVISORS LLC
-
Form SC 13D/A Arcutis Biotherapeutics, Filed by: ORBIMED ADVISORS LLC
-
Jubilant Therapeutics Appoints Dr. Robert Glassman to its Board of Directors
-
Form SC 13D/A Prevail Therapeutics Filed by: ORBIMED ADVISORS LLC
-
Form SC 13D/A Passage BIO, Inc. Filed by: ORBIMED ADVISORS LLC
-
Form 4 Prevail Therapeutics For: Jan 22 Filed by: ORBIMED ADVISORS LLC
-
Umoja Biopharma Appoints Dr. Robert Glassman to its Board of Directors
-
Form SC 13D Gracell Biotechnologies Filed by: ORBIMED ADVISORS LLC
-
Terns Announces FDA Clearance of Investigational New Drug (IND) Application for First-in-Human Phase 1 Trial of TERN-501, its THR-Beta Agonist in Development for the Treatment of NASH
-
Form SC 13D/A Prelude Therapeutics Filed by: ORBIMED ADVISORS LLC
-
Terns Completes Enrollment in Phase 2a Clinical Trial of TERN-101 in NASH Patients
-
Form 4 CTI BIOPHARMA CORP For: Jan 07 Filed by: ORBIMED ADVISORS LLC
-
Vivo Capital Appoints New Managing Partners and Partners
-
Form 3 Verona Pharma plc For: Jan 01 Filed by: ORBIMED ADVISORS LLC
-
Terns Appoints Three New Independent Directors to its Board
-
Pharvaris Expands Board of Directors with Appointment of David Meeker, M.D., as Chair and Robert Glassman, M.D., as Director
-
Terns Closes $87 Million Series C Financing to Advance NASH Portfolio
-
Form 4 ALPINE IMMUNE SCIENCES, For: Dec 28 Filed by: ORBIMED ADVISORS LLC
-
Form SC 13D/A ALPINE IMMUNE SCIENCES, Filed by: ORBIMED ADVISORS LLC
-
ClearPoint Neuro, Inc. Announces Funding of Additional $7.5M of Existing Convertible Note on Improved Terms
-
Form SC 13D Silverback Therapeutics, Filed by: ORBIMED ADVISORS LLC
-
Form SC 13D Kinnate Biopharma Inc. Filed by: ORBIMED ADVISORS LLC
-
Form 4 Silverback Therapeutics, For: Dec 08 Filed by: ORBIMED ADVISORS LLC
-
Syros Closes $90.5 Million Strategic Financing
-
Sinovac Reports Unaudited Third Quarter 2020 Financial Results
-
Thiel-backed therapy developer AbCellera looks to raise up to $391 million in IPO
-
Form 3 Kinnate Biopharma Inc. For: Dec 02 Filed by: ORBIMED ADVISORS LLC
-
Genenta to Appoint Stephen Squinto, Experienced Biotech Executive and Investor, as Chairman
-
Form SC 13D/A Keros Therapeutics, Inc. Filed by: ORBIMED ADVISORS LLC
-
Ikena Oncology Assembles Multi-Disciplinary Scientific Advisory Board
-
Form SC 13D/A Oric Pharmaceuticals, Filed by: ORBIMED ADVISORS LLC

